Relevant BNF section: 8.2.4
Around 2.5 million people worldwide have multiple sclerosis, of whom about 85,000 are in the UK.1 ▼Natalizumab (pronounced na-ta-liz-you-mab; Tysabri – Biogen Idec), the first in a new class known as selective adhesion-molecule inhibitors, is licensed in the UK as monotherapy for “highly active” relapsing/remitting multiple sclerosis.2 Here we review natalizumab and assess its place for patients with multiple sclerosis.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.